ClinicalTrials.gg
Active, not recruitingNCT05501717Updated Apr 9, 2026

Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants

A Phase 1 interventional study of ALXN2030 and Placebo in Healthy, sponsored by Alexion Pharmaceuticals, Inc.. Active, not recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-09.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The primary purpose of this study is to assess the safety and tolerability of single ascending doses of ALXN2030 in healthy participants.

Read the detailed description

Approximately 48 healthy adult participants (36 participants will be on ALXN2030 and 12 participants will be on placebo) are expected to be enrolled.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.

Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.

First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy participants
  • ≤ 450 msec at Screening and on admission (ie, on Day -1).
  • Participants of Japanese descent are defined as: First generation (born to 2 Japanese parents and 4 Japanese grandparents).
  • Participants of Japanese descent must be between 20 and 60 years of age.
  • within the range 18-32kg/m2 (inclusive) at Screening.

Exclusion criteria

Exclusion Criteria:

  • Current or recurrent disease
  • Current or relevant history of physical or psychiatric illness.
  • Any other significant disease or disorder that, in the opinion of the Investigator, may put the participant at risk.
  • Female participants who are pregnant or breastfeeding.
  • Major surgery or hospitalization within 90 days prior to dosing on Day1.
  • History of allergy or to an oligonucleotide or GalNAc moiety or any of ALXN2030.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    ALXN2030 Dose A

    ALXN2030 will be administered as a single dose.

    Drug: ALXN2030

  • Experimental
    ALXN2030 Dose B

    ALXN2030 will be administered as a single dose.

    Drug: ALXN2030

  • Experimental
    ALXN2030 Dose C

    ALXN2030 will be administered as a single dose.

    Drug: ALXN2030

  • Experimental
    ALXN2030 Dose D

    ALXN2030 will be administered as a single dose.

    Drug: ALXN2030

  • Experimental
    ALXN2030 Dose E

    ALXN2030 will be administered as a single dose.

    Drug: ALXN2030

  • Placebo comparator
    Placebo

    Placebo will be administered as a single dose.

    Drug: Placebo

Interventions

  • DrugALXN2030

    ALXN2030 will be administered subcutaneously as a single dose either as a manual SC injection or as an SC infusion via a syringe pump.

  • DrugPlacebo

    Placebo will be administered subcutaneously as a single dose either as a manual SC injection or as an SC infusion via a syringe pump.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)

    Time frame: Day 1 through through study completion, an average of 1 year

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    Time frame: Days 1 (predose; end of infusion (EOI); and 0.25, 0.5, 1, 2, 4, 6, 8, and 12 hours post-EOI), 2, 3, 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, and 127

  2. Time to Maximum Observed Plasma Concentration (Tmax)

    Time frame: Days 1 (predose; EOI; and 0.25, 0.5, 1, 2, 4, 6, 8, and 12 hours post-EOI), 2, 3, 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, and 127

  3. Area Under the Plasma Concentration Versus Time Curve From Time 0 (Dosing) to the Last Quantifiable Concentration (AUCt)

    Time frame: Days 1 (predose; EOI; and 0.25, 0.5, 1, 2, 4, 6, 8, and 12 hours post-EOI), 2, 3, 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, and 127

  4. Change from Baseline in Plasma Concentration of Complement Component 3 (C3) Protein

    Time frame: Baseline (Day 1) and study completion, an average of 1 year

  5. Change from Baseline in Serum Complement Functional Activity

    Time frame: Baseline (Day 1) and Day 127

  6. Number of Participants With Treatment-Emergent Antidrug Antibodies (ADAs)

    Time frame: Days 1 through study completion, an average of 1 year

07

Study locations

1 site
  • Research Site
    Harrow, HA1 3UJ, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in Oct 2025, 37 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2022
First posted
Aug 15, 2022
StartActual
Aug 16, 2022
Primary completionActual
Oct 9, 2025
CompletionEst.
Oct 14, 2026
Last update
Apr 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05501717
Responsible party
Sponsor
First posted
Aug 15, 2022
Start date
Aug 16, 2022
Primary completion
Oct 9, 2025
Completion
Oct 14, 2026 (estimated)
Last update
Apr 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion